Published in J Med Chem on August 12, 2004
Folding events in the 21-30 region of amyloid beta-protein (Abeta) studied in silico. Proc Natl Acad Sci U S A (2005) 1.43
Nanoimaging for protein misfolding and related diseases. J Cell Biochem (2006) 1.05
Effects of solvent on the structure of the Alzheimer amyloid-beta(25-35) peptide. Biophys J (2006) 1.04
Role of β-hairpin formation in aggregation: the self-assembly of the amyloid-β(25-35) peptide. Biophys J (2012) 0.91
Crystallization and preliminary X-ray diffraction analysis of the Fab fragment of WO2, an antibody specific for the Abeta peptides associated with Alzheimer's disease. Acta Crystallogr Sect F Struct Biol Cryst Commun (2008) 0.88
The stability of monomeric intermediates controls amyloid formation: Abeta25-35 and its N27Q mutant. Biophys J (2006) 0.87
Structural similarities and differences between amyloidogenic and non-amyloidogenic islet amyloid polypeptide (IAPP) sequences and implications for the dual physiological and pathological activities of these peptides. PLoS Comput Biol (2013) 0.86
Structural and functional properties of peptides based on the N-terminus of HIV-1 gp41 and the C-terminus of the amyloid-beta protein. Biochim Biophys Acta (2008) 0.83
Erythropoietin prevents PC12 cells from beta-amyloid-induced apoptosis via PI3K⁄Akt pathway. Transl Neurodegener (2012) 0.81
The interaction between amyloid-β peptides and anionic lipid membranes containing cholesterol and melatonin. PLoS One (2014) 0.79
Structural determination of Abeta25-35 micelles by molecular dynamics simulations. Biophys J (2010) 0.78
Aggregation of Aß(25-35) on DOPC and DOPC/DHA bilayers: an atomic force microscopy study. PLoS One (2014) 0.77
Peptide-lipid interactions: experiments and applications. Int J Mol Sci (2013) 0.77
Effects of transmitters and amyloid-beta peptide on calcium signals in rat cortical astrocytes: Fura-2AM measurements and stochastic model simulations. PLoS One (2011) 0.76
Amyloid β-peptide 25-35 self-assembly and its inhibition: a model undecapeptide system to gain atomistic and secondary structure details of the Alzheimer's disease process and treatment. ACS Chem Neurosci (2012) 0.76
Opposing Effects of Cucurbit[7]uril and 1,2,3,4,6-Penta-O-galloyl-β-d-glucopyranose on Amyloid β25-35 Assembly. ACS Chem Neurosci (2015) 0.75
Alzheimer's disease--a panorama glimpse. Int J Mol Sci (2014) 0.75
NMR structure of the water soluble Aβ17-34 peptide. Biosci Rep (2014) 0.75
Investigating the Neuroprotective Effects of Turmeric Extract: Structural Interactions of β-Amyloid Peptide with Single Curcuminoids. Sci Rep (2016) 0.75
Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacol Sin (2017) 0.75
Membrane-Accelerated Amyloid-β Aggregation and Formation of Cross-β Sheets. Membranes (Basel) (2017) 0.75
Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic. Nature (2012) 2.96
Solution structure of the Alzheimer amyloid beta-peptide (1-42) in an apolar microenvironment. Similarity with a virus fusion domain. Eur J Biochem (2002) 1.99
The tachykinin peptide family. Pharmacol Rev (2002) 1.82
The alpha-to-beta conformational transition of Alzheimer's Abeta-(1-42) peptide in aqueous media is reversible: a step by step conformational analysis suggests the location of beta conformation seeding. Chembiochem (2006) 1.70
Evaluation of the Dmt-Tic pharmacophore: conversion of a potent delta-opioid receptor antagonist into a potent delta agonist and ligands with mixed properties. J Med Chem (2002) 1.40
Dmt and opioid peptides: a potent alliance. Biopolymers (2003) 1.40
The chemokine Bv8/prokineticin 2 is up-regulated in inflammatory granulocytes and modulates inflammatory pain. Proc Natl Acad Sci U S A (2009) 1.24
Potent delta-opioid receptor agonists containing the Dmt-Tic pharmacophore. J Med Chem (2002) 1.23
[Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor. Br J Pharmacol (2002) 1.14
Structure-activity studies on neuropeptide S: identification of the amino acid residues crucial for receptor activation. J Biol Chem (2006) 1.13
Interaction of sweet proteins with their receptor. A conformational study of peptides corresponding to loops of brazzein, monellin and thaumatin. Eur J Biochem (2004) 1.11
Neurobiology, pharmacology, and medicinal chemistry of neuropeptide S and its receptor. Med Res Rev (2010) 1.09
Anxiolytic-like effect of neuropeptide S in the rat defensive burying. Peptides (2008) 1.08
Synthesis and biological activity of human neuropeptide S analogues modified in position 5: identification of potent and pure neuropeptide S receptor antagonists. J Med Chem (2009) 1.08
Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease. J Neurosci (2005) 1.06
Long-lasting antinociceptive spinal effects in primates of the novel nociceptin/orphanin FQ receptor agonist UFP-112. Pain (2009) 1.05
Anxiolytic- and antidepressant-like activities of H-Dmt-Tic-NH-CH(CH2-COOH)-Bid (UFP-512), a novel selective delta opioid receptor agonist. Peptides (2007) 1.05
In vitro and in vivo pharmacological characterization of the neuropeptide s receptor antagonist [D-Cys(tBu)5]neuropeptide S. J Pharmacol Exp Ther (2008) 1.05
Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors. Eur J Pharmacol (2004) 1.04
6-N,N-dimethylamino-2,3-naphthalimide: a new environment-sensitive fluorescent probe in delta- and mu-selective opioid peptides. J Med Chem (2006) 1.02
UFP-101, a peptide antagonist selective for the nociceptin/orphanin FQ receptor. CNS Drug Rev (2005) 1.01
New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores. J Med Chem (2006) 1.00
Solution structure of ZASP PDZ domain; implications for sarcomere ultrastructure and enigma family redundancy. Structure (2004) 0.99
Triazine compounds as antagonists at Bv8-prokineticin receptors. J Med Chem (2008) 0.99
Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem (2006) 0.97
The mechanism of interaction of sweet proteins with the T1R2-T1R3 receptor: evidence from the solution structure of G16A-MNEI. J Mol Biol (2003) 0.97
Further studies on the pharmacological profile of the neuropeptide S receptor antagonist SHA 68. Peptides (2010) 0.97
Highly selective fluorescent analogue of the potent delta-opioid receptor antagonist Dmt-Tic. J Med Chem (2004) 0.96
Evolution of the Bifunctional Lead μ Agonist / δ Antagonist Containing the Dmt-Tic Opioid Pharmacophore. ACS Chem Neurosci (2010) 0.96
Activation of DOR attenuates anoxic K+ derangement via inhibition of Na+ entry in mouse cortex. Cereb Cortex (2008) 0.96
Direct influence of C-terminally substituted amino acids in the Dmt-Tic pharmacophore on delta-opioid receptor selectivity and antagonism. J Med Chem (2004) 0.96
Pharmacological profile of NOP receptors coupled with calcium signaling via the chimeric protein G alpha qi5. Naunyn Schmiedebergs Arch Pharmacol (2009) 0.95
Interaction of calmodulin with the phosphofructokinase target sequence. FEBS Lett (2004) 0.95
A new ligand for the urotensin II receptor. Br J Pharmacol (2002) 0.95
Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior. J Neurosci (2004) 0.95
Synthesis and biological activity of human neuropeptide S analogues modified in position 2. J Med Chem (2008) 0.95
Conformation-activity relationship of neuropeptide S and some structural mutants: helicity affects their interaction with the receptor. J Med Chem (2007) 0.94
In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor. Peptides (2007) 0.93
Further studies at neuropeptide s position 5: discovery of novel neuropeptide S receptor antagonists. J Med Chem (2009) 0.92
Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24. Eur J Pharmacol (2009) 0.92
Central injections of nocistatin or its C-terminal hexapeptide exert anxiogenic-like effect on behaviour of mice in the plus-maze test. Br J Pharmacol (2002) 0.91
Conversion of the potent delta-opioid agonist H-Dmt-Tic-NH-CH(2)-bid into delta-opioid antagonists by N(1)-benzimidazole alkylation(1). J Med Chem (2005) 0.91
Immunosensing by a Synthetic Ligand-Gated Ion Channel Financial support from the board of the Swiss Federal Institutes of Technology (SPP Minast, 7.06) is acknowledged. We thank G. Corradin for numerous discussions and J. Lakey for critical reading of the manuscript. Angew Chem Int Ed Engl (2001) 0.91
Pharmacological characterization of the nociceptin receptor which mediates reduction of alcohol drinking in rats. Peptides (2002) 0.90
Protein-protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase. Proc Natl Acad Sci U S A (2011) 0.90
Unique high-affinity synthetic mu-opioid receptor agonists with central- and systemic-mediated analgesia. J Med Chem (2003) 0.89
Conformationally constrained opioid ligands: the Dmt-Aba and Dmt-Aia versus Dmt-Tic scaffold. Bioorg Med Chem Lett (2008) 0.89
The nociceptin/orphanin FQ-NOP receptor antagonist effects on an animal model of sepsis. Intensive Care Med (2008) 0.89
Identification of the spiro(oxindole-3,3'-thiazolidine)-based derivatives as potential p53 activity modulators. J Med Chem (2010) 0.89
Synthesis and opioid activity of N,N-dimethyl-Dmt-Tic-NH-CH(R)-R' analogues: acquisition of potent delta antagonism. Bioorg Med Chem (2003) 0.89
In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen5,DTrp7,Dab8]urotensin II(4-11) (UFP-803). Br J Pharmacol (2006) 0.89
Pharmacological profile of nociceptin/orphanin FQ receptors. Clin Exp Pharmacol Physiol (2002) 0.89
Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release. J Neurochem (2004) 0.89
[Arg(14),Lys(15)]nociceptin, a highly potent agonist of the nociceptin/orphanin FQ receptor: in vitro and in vivo studies. J Pharmacol Exp Ther (2002) 0.89
Chronic treatment with the selective NOP receptor antagonist [Nphe 1, Arg 14, Lys 15]N/OFQ-NH 2 (UFP-101) reverses the behavioural and biochemical effects of unpredictable chronic mild stress in rats. Psychopharmacology (Berl) (2009) 0.88
Gait patterns in Parkinsonian patients with or without mild cognitive impairment. Mov Disord (2012) 0.88
Structure-activity study at positions 3 and 4 of human neuropeptide S. Bioorg Med Chem (2008) 0.88
Solution structure of the C1-subdomain of Bacillus stearothermophilus translation initiation factor IF2. Protein Sci (2005) 0.88
Hypothalamic neuropeptide S receptor blockade decreases discriminative cue-induced reinstatement of cocaine seeking in the rat. Psychopharmacology (Berl) (2012) 0.88
Effect of δ-opioid receptor activation on BDNF-TrkB vs. TNF-α in the mouse cortex exposed to prolonged hypoxia. Int J Mol Sci (2013) 0.87
Solution structure of a chemosensory protein from the desert locust Schistocerca gregaria. Biochemistry (2006) 0.87
Identification of an achiral analogue of J-113397 as potent nociceptin/orphanin FQ receptor antagonist. Bioorg Med Chem (2005) 0.86
Copper binding to the neurotoxic peptide PrP106-126: thermodynamic and structural studies. Chembiochem (2004) 0.86
Ligands raise the constraint that limits constitutive activation in G protein-coupled opioid receptors. J Biol Chem (2013) 0.86
Synthesis and separation of the enantiomers of the neuropeptide S receptor antagonist (9R/S)-3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68). J Med Chem (2011) 0.86
Neuropeptide S: a novel regulator of pain-related amygdala plasticity and behaviors. J Neurophysiol (2013) 0.86
Pharmacological characterization of tachykinin tetrabranched derivatives. Br J Pharmacol (2014) 0.86
Pharmacological profile of nociceptin/orphanin FQ receptors regulating 5-hydroxytryptamine release in the mouse neocortex. Eur J Neurosci (2004) 0.86
Proinflammatory and vasodilator effects of nociceptin/orphanin FQ in the rat mesenteric microcirculation are mediated by histamine. Am J Physiol Heart Circ Physiol (2007) 0.85
Structure-activity studies on the nociceptin/orphanin FQ receptor antagonist 1-benzyl-N-{3-[spiroisobenzofuran-1(3H),4'-piperidin-1-yl]propyl} pyrrolidine-2-carboxamide. Bioorg Med Chem (2009) 0.85